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ABSTRACT 
4-Hydroxynonenal (HNE), a highly reactive lipid peroxidation product, may adversely modify 
proteins. Accumulation of HNE-modified proteins may be responsible for pathological lesions 
associated with oxidative stress. The objective of this work was to determine how HNE-modified 
proteins are removed from cells. The data showed that αB-crystallin modified by HNE was 
ubiquitinated at a faster rate than that of native αB-crystallin in a cell-free system. However, its 
susceptibility to proteasome-dependent degradation in the cell-free system did not increase. 
When delivered into cultured lens epithelial cells, HNE-modified αB-crystallin was degraded at 
a faster rate than that of unmodified αB-crystallin. Inhibition of the lysosomal activity stabilized 
HNE-modified αB-crystallin, but inhibition of the proteasome activity alone had little effect. To 
determine if other HNE-modified proteins are also degraded in a ubiquitin-dependent lysosomal 
pathway, lens epithelial cells were treated with HNE and the removal of HNE-modified proteins 
in the cells was monitored. The levels of HNE-modified proteins in the cell decreased rapidly 
upon removal of HNE from the medium. Depletion of ATP or the presence of MG132, a 
proteasome/lysosome inhibitor, resulted in stabilization of HNE-modified proteins. However, 
proteasome-specific inhibitors, lactacystin-β-lactone and epoxomicin, could not stabilize HNE-
modified proteins in the cells. In contrast, chloroquine, a lysosome inhibitor, stabilized HNE-
modified proteins. The enrichment of HNE-modified proteins in the fraction of ubiquitin 
conjugates suggests that HNE-modified proteins are preferentially ubiquitinated. Taken together, 
these findings show that HNE-modified proteins are degraded via a novel ubiquitin and 
lysosomal-dependent but proteasome-independent pathway. 
Key words: lipid peroxidation ● hydroxynonenal ● proteasome ● protein quality control 
xidative stress is known to cause various forms of damage to most types of cells, 
including protein oxidation, DNA breaks, and lipid peroxidation (1–3, 4, 5). The 4-
hydroxynonenal (HNE), generated by peroxidation of polyunsaturated fatty acids, such O 
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 as arachidonic and linoleic acids, is the most reactive and cytotoxic product of lipid peroxidation 
(6, 7). HNE modification is also frequently used as a marker of lipid peroxidation and oxidative 
stress in vivo (7). Lysine, histidine, and cysteine residues in proteins and nucleophilic groups in 
DNA are all potential targets for HNE (8). Higher levels of HNE-modified proteins have been 
detected in animal and human tissues under certain pathological conditions, suggesting that 
accumulation of HNE-modified proteins is involved in the pathophysiology of degenerative 
diseases (9, 10) and cellular aging (11). It has also been shown that both exogenously added 
HNE and endogenously generated HNE can form adducts with various intracellular proteins (12, 
13). Proteins modified by HNE may alter their structures and functions, and accumulation of 
such modified proteins may be cytotoxic. Thus, HNE-modified proteins must be removed to 
avoid disruption of the cellular functions. 
The extent of accumulation of oxidatively modified proteins depends on the rate of production 
and the rate of degradation by proteases (1). It is known that, in most types of cells, intracellular 
proteolytic enzymes selectively degrade oxidized proteins (14, 15). Proteolytic capabilities are 
therefore considered to be secondary defense systems that can delay the accumulation of 
adversely modified proteins (1, 16, 17). The majority of intracellular proteins are degraded either 
by the lysosomal pathway or by the ubiquitin-proteasome pathway (UPP). The lysosome is 
responsible for the degradation of membrane or extracellular proteins that enter cells by 
endocytosis (18). The UPP is a major proteolytic pathway in eukaryotic cells, and it is 
responsible for conditional degradation of intracellular short-lived regulatory proteins or 
abnormal cytosolic and nuclear proteins (19–23). In the UPP, proteins targeted for proteasomal 
degradation are first ligated to multiple ubiquitin molecules. Polyubiquitination targets proteins 
for degradation by the 26S proteasome in an ATP-dependent manner (23, 24). Since both the 
formation of ubiquitin conjugates and subsequent degradation of the conjugates require ATP, a 
hallmark of the UPP is the ATP dependence. In some cases, ubiquitination of proteins, 
particularly membrane receptors, facilitate their internalization and degradation by the 
endosome-lysosome pathway (25). 
We demonstrated previously that the UPP is involved in degradation of oxidized proteins in cell-
free systems and within intact cells (26). In this study, we evaluated the role of the UPP in 
degradation of HNE-modified proteins. We found that the HNE-modified proteins were 
ubiquitinated at a faster rate than their nonmodified counterpart, but the susceptibility of HNE-
modified proteins to proteasome-dependent degradation was not significantly different from that 
of unmodified proteins. Although depletion of ATP resulted in the accumulation of HNE-
modified proteins in cells, proteasome-specific inhibitors had little effect on the degradation of 
HNE-modified proteins. In contrast, inhibition of the lysosomal activity stabilized the HNE-
modified proteins. These data indicate that the HNE modified proteins are degraded by a novel 
ubiquitin-dependent lysosomal pathway. 






I-protein A were supplied by PerkinElmer Life Science (Boston, MA). 
Nitrocellulose membrane and protein molecular mass standards were purchased from Bio-Rad 
(Richmond, CA). BioPORTER protein delivery reagent was purchased from Gene Therapy 
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 Systems (San Diego, CA). Carbobenzoxyl-leucinyl-leucinyl-leucinal-H (MG-132) and ubiquitin 
aldehyde (Ubal) were purchased from Bostonbiochem (Cambridge, MA). HNE was purchased 
from Cayman Chemical Company (Ann Arbor, MI). The antibodies to HNE-modified proteins 
were produced in Dr. L. Szweda’s laboratory. Rabbit reticulocytes were purchased from Pel-
Freez Biologicals (Rogers, AR). Ni-NTA magnetic agarose beads were purchased from Qiagen 
(Valencia, CA). Unless specified, all other reagents were purchased from Sigma (St. Louis, MO) 
and were the highest grade available. 
Preparation of 125 I-labeled proteins 
Proteins were radioiodinated essentially as described previously (27). In brief, the protein (200 µg) was mixed with Na125I (200 µCi). The iodination reaction was started by addition of 
chloramine T, and the vials were shaken for 2 min at room temperature. Then the reaction was 
terminated by the addition of sodium metabisulfite and sodium iodide. Free 
125
I and small protein 
fragments were removed from the protein solution by Centricon-10 microconcentrators 
(Millipore Corporation, Bedford, MA). 
Expression and purification of Ubc4 
The cloned cDNA (2E isoform of mammalian Ubc4-1) was expressed in E. coli using the T7 
promoter in the pET11d-expression vector (Novagen Inc., Madison, WI). The plasmid was 
generously provided by Dr. Simon Wing and was transformed into BL21 E. coli (Novagen Inc.). 
The expression and purification of Ubc4-1 were performed as described previously (28). 
Modification of α-crystallin with HNE 
The mixture of αA- and αB-crystallin was purified from bovine lenses as described previously 
(29). The recombinant αB-crystallin was expressed and purified as described previously (30). 
Native α-crystallins (2.5 mg/ml) were treated with 0-200 µM of HNE in phosphate-buffered 
saline (PBS), pH 7.4, at 37°C for 2 h. To determine the effects of HNE modification on the 
susceptibility to degradation, recombinant αB-crystallin was first iodinated as described above 
and the iodinated αB-crystallin was incubated with or without 100 µM HNE at 37°C for 2 h. 
Free HNE and free 
125
I were removed by centrifugation with Centricon-10 microconcentrators. 
Proteolysis assays 
Rabbit reticulocyte lysate was prepared as described previously by Ciechanover et al. (31). 
125
I-
labeled αB-crystallins treated with or without 100 µM HNE were used as substrates for the 
degradation assay. ATP-dependent degradation was performed in 25 µl assays that contained 15 µl of rabbit reticulocyte lysate and 10 µl of buffer [50 mM Tris-HCl (pH 7.8) containing 5 mM 
MgCl2, 2 mM DTT, 2 mM ATP, 10 mM creatine phosphate, 4.5 µg creatine phosphokinase, 2 µg 
ubiquitin, and 2 µg 125I-labeled substrate]. To determine the ATP-independent degradation, ATP, 
creatine phosphate, and creatine phosphokinase were replaced with 30 mM 2-deoxyglucose. All 
these assays were supplemented with 0.5 µg recombinant Ubc4. MG132 was added to selected 
tubes at a final concentration of 80 µM to determine the involvement of the proteasome. The 
degradation was initiated by the addition of 3-5 × 10
4
 cpm of 
125
I-labeled α-crystallins (2 µg). 
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 The reaction was carried out at 37°C for 2 h and then stopped by the addition of 400 µl of 1% 
(w/v) bovine serum albumin, immediately followed by 100 µl of 100% (w/v) trichloroacetic acid 
(TCA). After standing on ice for 10 min, the samples were centrifuged 14,000 rpm at 4°C for 10 
min. Aliquots of supernatant (400 µl) were counted to determine the TCA-soluble radioactivity. 
The amount of radioactivity in the pellet was also determined. The extent of degradation was 
determined as the percentage of 
125
I released as TCA-soluble fragments. Each assay was 
performed in duplicate. 
Ubiquitin conjugation assays 
Ubiquitin-protein conjugates were formed by incubation of 
125
I-labeled αB-crystallins with 
proteasome-free fraction II prepared from rabbit reticulocytes. Fraction II was prepared as 
described by Ciechanover et al. (31), and the proteasome was removed from fraction II by 
centrifuging at 100,000 g for 5 h (32). All ubiquitination assays were done in 25 µl containing 15 µl of proteasome-free Fraction II and 10 µl of reaction buffer (50 mM Tris, pH 7.8, 5 mM 
MgCl2, 2 mM DTT, 2 mM ATP, 10 mM creatine phosphate, 4.5 µg creatine phosphokinase, 2 µg 
of ubiquitin). For negative control, ubiquitin was omitted from the assay. The reaction was 
initiated by the addition of 3-5 × 10
6
 cpm of 
125
I-labeled substrates and terminated by addition of 
25 µl of 2x Laemmli buffer (33) after incubation at 37°C for 1 h. Proteins in the reaction mixture 
were separated by SDS-PAGE and transferred to nitrocellulose. After autoradiography, the 
membrane was probed for ubiquitin conjugates with antibodies to ubiquitin. The immunoreactive 
bands were visualized using the SuperSignal Chemiluminescent Kit (Pierce, Rockford, IL). The 
relative amounts of ubiquitin-protein conjugates were quantified by scanning densitometry. 
Degradation of HNE-modified proteins in lens epithelial cells 
Human lens epithelial cells (HLEC, SRA 01/04 cell line) were established at Dr. V. Reddy’s 
laboratory. The HLEC were cultured in Dulbeco’s Modified Eagle’s Medium (DMEM) 
containing 10% (v/v) fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml), 
and amphotericin (250 ng/ml), at 37°C in a humidified incubator with 5% CO2. 
125
I-labeled αB-
crystallins were delivered into HLEC using BioPORTER protein delivery reagent according to 
the instructions of the manufacturer. An equal amount 
125
I-labeled unmodified or HNE-modified αB-crystallins (5x104 cpm, ~1 µg αB-crystallins) were mixed with BioPORTER protein delivery 
reagent and added to each dish of HLEC (35 mm dish). After incubation for 2 h, the medium was 
removed and the cells were washed with PBS twice to remove any 
125
I-αB-crystallins that did 
not enter the cells. Then the cells were incubated for another 4 h in the absence or presence of 
MG132 (5 µM), clasto-lactacystin-β-lactone (10 µM), or chloroquine (100 µM). Then the cells 
were collected and proteins were resolved by SDS-PAGE. Levels of 
125
I-labeled αB-crystallins 
remained in the cells were determined by autoradiography. 
To determine the removal of intracellular HNE-modified proteins, subconfluent cultures were 
washed once gently with PBS and then incubated at 37°C for 1 h with 5 µM HNE in PBS 
containing 5 mM glucose, 0.3 mM CaCl2, and 0.62 mM MgCl2. Control cells were incubated in 
the same conditions and for the same period of time but without HNE. After treatment with 
HNE, cells were washed once with PBS and cultured in normal medium for 0-8 h. The cells were 
collected at the indicted time points with a cell scraper. The cell pellets were lysed in 10 mM 
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 Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.1% SDS, 20 mM N-ethylmaleimide, and 2 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride on ice for 30 min with occasional vortexing. After 
centrifugation (14,000 rpm, 15 min, 4°C), protein concentrations in the supernatants were 
determined with the modified method of Lowry, using the protein assay kit from Sigma 
according to the instructions of the manufacturer. Supernatants of the cells were resolved on 
12% SDS gels and transferred to nitrocellulose membranes. After being blocked with 5% fat-free 
milk in TST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.02% Tween 20), the membrane was 
probed with an antibody specific to HNE-modified proteins, followed by goat anti-rabbit IgG 
conjugated to horseradish peroxidase. The immunoreactive bands were visualized using the 
SuperSignal Chemiluminescent Kit (Pierce). The ATP depletion was achieved by incubation 
with 8 µM antimycin A and 20 mM 2-deoxyglucose (34). 
Determination of HNE-modified proteins in the fraction of ubiquitin conjugates 
To facilitate the isolation of ubiquitin conjugates, a recombinant adenovirus encoding an 
RGS(His)6-tagged ubiquitin was constructed (Shang et al., unpublished observations). Cultured 
HLEC were infected with an equivalent amount of the recombinant adenovirus or the control 
adenovirus for 48 h prior HNE treatment. After removal of HNE from the medium for 1 h, cells 
were collected and lysed in a buffer containing 8 M urea and 10 mM imidazole. The lysates were 
mixed with Ni-NTA magnetic agarose beads (Qiagen) for 1 h. This mixture was then layered 
onto a 50 µl column of Ni-NTA resin. After extensive wash with buffered 8 M urea containing 
20-50 µM imidazole, the bound proteins were then eluted from the column using buffered 8 M 
urea containing 250 mM imidazole. Protein concentrations in the eluate were determined and 
resolved in SDS-PAGE. Levels of HNE-modified proteins in the eluate were determined by 
Western blot. An equal amount of proteins that bound to Ni-NTA resin nonspecifically (proteins 
from cells that do not express his-tagged proteins) was used as negative control. 
RESULTS 
Ubiquitination and degradation of HNE-modified protein in cell-free systems 
Western blot analysis using polyclonal antibodies that specifically recognize HNE-modified 
proteins showed that α-crystallins were modified by HNE in a dose-dependent manner (Fig. 1). 
The molecular masses of the majority of these HNE-modified products were ~20 kDa, which 
corresponds to the molecular masses of the α-crystallin monomers. With increasing 
concentrations of HNE, a band at molecular mass ~40 kDa showed strong reaction with 
antibodies to HNE adducts. This 40 kDa HNE-reactive band comigrated with the dimer of α-
crystallin. At higher HNE concentrations, some lower mass HNE adducts were also observed 
(Fig. 1). These lower molecular masses adducts are most likely the products of fragmentation of 
HNE-modified α-crystallins. Whereas the ratio of αA/αB was ~3:1 in the α-crystallin 
preparation (Fig. 1, lower panel), the levels of HNE modified αB-crystallin were ~3-fold higher 
than those of HNE-modified αA-crystallin (Fig. 1, upper panel). These data indicate that αB-
crystallin is more susceptible than αA-crystallin to being modified by HNE. To test the 
susceptibility of HNE-modified α-crystallins to ubiquitination and degradation, we chose to use 
recombinant αB-crystallin treated with 100 µM HNE for 2 h. This level of HNE resulted in 
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 modification of the majority of αB-crystallin but left most of the lysine residues available for 
ubiquitination. 
To compare the susceptibilities of untreated αB-crystallins and HNE-modified αB-crystallins to 
being ubiquitinated, the untreated and HNE-modified αB-crystallins were incubated with ATP 
and Ubc4-supplemented proteasome-free fraction II in the presence or absence of 20 µM 
ubiquitin. Autoradiography shows that in the absence of ubiquitin, the αB-crystallins migrated as 
a single band (Fig. 2A, lanes 3 and 4). After incubation in the presence of ubiquitin, ~5% αB-
crystallin migrated at a slower rate (Fig. 2A, lanes 1 and 2). This slower migrating band 
colocalized with a ubiquitinated protein (Fig. 2A, lanes 5 and 6), indicating that the slower 
migrating band was the mono-ubiquitinated form of αB-crystallin. Longer exposure of the film 
revealed that <1% of total αB-crystallin was polyubiquitinated (data not shown). Levels of 
ubiquitinated HNE-modified αB-crystallin were ~2-fold greater than those for untreated αB-
crystallin (Fig. 2A, compare lane 2 with 1 and lane 6 with 5), indicating that HNE-modified αB-
crystallin is a preferred substrate for ubiquitination. 
The susceptibility of the HNE-modified αB-crystallin to proteasome-dependent degradation was 
subsequently determined. During the 2 h of incubation with reticulocyte lysate, the ATP-
independent degradation of untreated αB-crystallin and HNE-modified αB-crystallin was ~5 and 
3%, respectively (Fig. 2B). If ATP was added to the degradation system, the degradation rates 
for untreated αB-crystallin and HNE-modified αB-crystallin were 30 and 33% during the same 
period of incubation (Fig. 2B). Furthermore, the presence of MG132 blocked the majority of 
ATP-dependent degradation of untreated α-crystallins and HNE-modified αB-crystallins (Fig. 
2B), suggesting that the ATP-dependent degradation observed under these conditions was mainly 
proteasome dependent. It should be pointed out that although MG132 inhibits both the 
proteasome and the lysosome activity in cells, the lysosome enzymes are not active at the pH 
used in this assay. Therefore, the effects of MG132 under this experimental setting reflect the 
proteasome activity but not the lysosome activity. The above data indicate that both untreated 
and HNE-modified αB-crystallins are degraded by the ubiquitin-proteasome pathway. However, 
the difference of proteasome-dependent degradation between untreated and HNE-modified αB-
crystallins was not statistically significant. 
Degradation of HNE-modified proteins in HLEC 
The increased susceptibility of HNE-modified proteins to being ubiquitinated without a 
significant alteration in their susceptibility to being degraded by the proteasome in the cell-free 
systems suggests that HNE-modified proteins may be degraded by a proteolytic pathway other 
than the proteasome pathway. To further determine how the HNE-modified proteins were 
removed from intact cells, 
125
I-labeled, untreated, or HNE-modified αB-crystallins were 
delivered into cultured HLEC using the BioPORTER protein delivery reagent. Both untreated 
and HNE-modified αB-crystallins were efficiently delivered into HLEC (~50% of the 125I-
labeled crystallins), and the delivery efficiencies between untreated and HNE-modified αB-
crystallins were comparable (data not shown). In the absence of protease inhibitors, both 
untreated and HNE-modified αB-crystallins were degraded rapidly, and it appears that HNE-
modified αB-crystallin was degraded faster than unmodified αB-crystallin (Fig. 3, compare lane 
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 2 with 1). This result is consistent with our previous observations that native α-crystallins are 
rapidly degraded by the ubiquitin-proteasome pathway. In the presence of MG132, which 
inhibits both the proteasome and the lysosome, both untreated and HNE-modified αB-crystallins 
were stabilized (Fig. 3, lanes 3 and 4). To determine if the proteasome is involved in degradation 
of HNE-modified αB-crystallin in the cells, we tested the effect of a specific proteasome 
inhibitor (clasto-lactacystin-β-lactone) on levels of αB-crystallins in the cells. In contrast to 
MG132, clasto-lactacystin-β-lactone partially stabilized untreated αB-crystallin in the cells, but 
it did not stabilize the HNE-modified αB-crystallin (Fig. 3, compare lanes 5 and 6 with lanes 1 
and 2, respectively). In the presence of lactacystin-β-lactone, the levels of untreated αB-
crystallin that remained in the cells were much higher than those of HNE-modified αB-crystallin 
(Fig. 3, compare lane 5 with 6). This greater difference is due to the preferential stabilization of 
untreated αB-crystallin by the proteasome inhibitor. The inability of clasto-lactacystin-β-lactone, 
in contrast to MG132, to stabilize HNE-modified αB-crystallin suggests that HNE-modified αB-
crystallin was degraded by the lysosome pathway, since MG132 not only inhibits the 
proteasome, it also inhibits cathepsins in the lysosome. To confirm the involvement of the 
lysosome in degradation of HNE-modified αB-crystallin, we determined the effect of 
chloroquine (a lysosome inhibitor) on the stability of HNE-modified αB-crystallin in the cells. 
Indeed, HNE-modified αB-crystallins were partially stabilized in the presence of chloroquine 
(Fig. 3, lanes 7 and 8) and the levels of untreated and HNE-modified αB-crystallins were 
comparable under these conditions, indicating that HNE-modified αB-crystallin was 
preferentially degraded by the lysosomal pathway. If clasto-lactacystin-β-lactone and 
chloroquine were added together to the cells, both untreated and HNE-modified αB-crystallins 
were stabilized and levels of crystallins remaining in the cells were similar to those observed in 
the presence of MG132 (Fig. 3, compare lanes 9 and 10 with lanes 3 and 4). Longer exposure of 
the film revealed a small fraction (<1%) of 
125
I-labeled αB-crystallin migrated at a slower rate. 
Based on the molecular weight, the slower migrating moiety appears to be mono-ubiquitinated αB-crystallin (Fig. 3, upper panel). This putative mono-ubiquitinated αB-crystallin was more 
readily detectable in the presence of MG132 (Fig. 3, upper panel, lanes 3 and 4) or in the 
presence of both lactacystin-β-lactone and chloroquine (Fig. 3, lanes 9 and 10). Taken together, 
these data indicate that untreated αB-crystallin is a good substrate for the ubiquitin-proteasome 
pathway, but HNE-modified αB-crystallin is a preferred substrate for the lysosome pathway. 
To determine if the ubiquitin-dependent lysosomal degradation of HNE-modified αB-crystallin 
pertains to other HNE-modified proteins, HLEC were treated with HNE and the effects of 
proteasome and lysosome inhibitors on the removal of HNE-modified proteins were determined. 
After 1 h of treatment with 5 µM HNE, several of the cellular proteins formed adducts with HNE 
(Fig. 4–6, lane 2). Upon removal of HNE from the medium, levels of the HNE-modified proteins 
decreased. After 24 h of recovery in HNE-free medium, the levels of HNE-modified proteins 
returned almost to the levels observed in untreated cells, indicating that HNE-modified proteins 
are rapidly removed from the cells (Fig. 4, compare lanes 3, 5, and 7 with lane 2). To explore 
which of proteolytic pathways are involved in the removal of HNE-modified proteins, we first 
evaluated the effect of MG132, which inhibits both the proteasomal and the lysosomal pathways, 
on the removal of the HNE-modified proteins. In contrast to the rapid removal of HNE-modified 
proteins in the absence protease inhibitors, the HNE-modified proteins were significantly 
stabilized in cells treated with MG132 (Fig. 4, compare lanes 4, 6, and 8 with lanes 3, 5, and 7, 
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 respectively), suggesting that the HNE-modified proteins in the cells are removed via proteolytic 
degradation. To determine if the proteasome pathway was involved, we determined the effects of 
proteasome specific inhibitors on the removal of HNE-modified proteins from cells. Both clasto-
lactacystin-β-lactone and epoxomicin treatment increased the level of ubiquitin conjugates (data 
not shown), indicating that the proteasome activity was inhibited. However, neither clasto-
lactacystin-β-lactone nor epoxomicin slowed the removal of HNE-modified proteins from the 
cells (Fig. 5, compare lanes 5 and 6 with lane 3). These data indicate that the proteasome did not 
play a major role in the removal of HNE-modified proteins from the lens cells. In contrast, 
chloroquine inhibited the removal of HNE-modified proteins (Fig 5, compare lane 7 with lane 3). 
These data indicate that the majority of HNE-modified proteins in intact cells are degraded by 
the lysosomal pathway, rather than by the proteasome. The effect of these protease inhibitors on 
the removal of HNE-modified proteins was not due to cytotoxicity, because cells were viable as 
judged by Trypan blue exclusion assay (data not shown). There were no detectable changes in 
cell morphology under these conditions. 
Because the HNE-modified proteins are preferred substrates for ubiquitination in cell-free 
systems (Fig. 2), we determined if ubiquitination is involved in the lysosomal degradation of 
HNE-modified proteins. A hallmark of ubiquitination is the requirement of ATP. Levels of 
ubiquitin conjugates are often correlated with intracellular ATP levels. When intracellular ATP 
was depleted with antimycin A and 2-deoxyglucose (34), levels of endogenous ubiquitin 
conjugates decreased significantly (Fig. 6A, lower panel) and the removal of HNE-modified 
proteins was significantly slowed as compared with cells with normal levels of ATP (Fig. 6A, 
upper panel, compare lane 5 with lane 4), indicating the degradation of HNE-modified proteins 
is ATP dependent. To further determine if ubiquitination is involved in the lysosomal 
degradation of HNE-modified proteins, we expressed (His)6-tagged ubiquitin in the cells and 
isolated ubiquitin conjugates from HNE-treated cells. Figure 6B showed that the fraction of 
ubiquitin conjugates was enriched with of HNE-modified proteins as compared with the proteins 
that were nonspecifically bound to the Ni-NTA resin. These data imply that HNE-modified 
proteins are recognized by the ubiquitinating system and targeted to the lysosome for 
degradation. 
DISCUSSION 
An increasing body of evidence suggests that HNE, a lipid peroxidation product, is involved in 
many of the pathophysiological lesions associated with oxidative stress in cells and tissues (35). 
HNE exhibits a wide variety of biological effects including inhibition of DNA and protein 
synthesis (7), glutathione depletion (36), and inhibition of various enzymes (37). Cellular 
proteins are the primary targets of HNE modification via forming Michael adducts on lysine, 
histidine and cysteine residues, or through formation of Schiff bases with lysine residues (38). It 
appears that the efficient removal of HNE-modified proteins is essential, because accumulation 
of HNE-modified proteins is associated with many cellular dysfunctions (9, 10) and cellular 
aging (11). This study elucidated how HNE-modified proteins are removed from the cells. 
We found that HNE-modified proteins were preferentially ubiquitinated in a cell-free system 
(Fig. 2A). However, the rate of proteasome-dependent degradation of the HNE-modified proteins 
was not significantly different from that of unmodified proteins in the cell-free system (Fig. 2B). 
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 Similarly, we found that HNE-modified proteins are efficiently removed from lens epithelial 
cells by a proteolytic mechanism (Figs. 3–5). Although ATP is required for this proteolytic 
pathway (Fig. 6A), inhibition of the cellular proteasome activity did not affect the removal of 
HNE-modified proteins (Figs. 3 and 5). In contrast, inhibition of the lysosome activity resulted 
in an accumulation of HNE-modified proteins in the cells (Figs. 3 and 5). Moreover, it suggests 
that HNE-modified proteins are preferentially ubiquitinated by the ubiquitin-conjugating system 
since ubiquitin conjugates isolated from HNE-treated cells were enriched with HNE-modified 
proteins (Fig. 6B). Taken together, these results indicate that, like other types of damaged 
proteins, HNE-modified proteins are also recognized by the ubiquitin-conjugating system and 
the ubiquitin-conjugating system may serve as a common mechanism to recognize various types 
of modified or damaged proteins, although different E2 s and E3 s may be used to ubiquitinate 
different types of damaged proteins. The ubiquitinated proteins can either be degraded by the 
proteasome (24, 39) or by the lysosome (23, 40, 41). However, the mechanism for the 
differential destinations of the ubiquitinated proteins remains elusive. The destination of 
ubiquitinated proteins could be determined by the nature of the protein substrates or by the 
structures of the ubiquitin conjugates. For example, proteins destined to the proteasome are often 
polyubiquitinated (24) and proteins destined to the lysosome are often mono-ubiquitinated (42). 
The putative mechanism for substrate recognition is summarized in Fig. 7. 
Available data regarding the degradation of HNE-modified proteins are limited. One study 
showed that HNE-modified proteins in homogenates of kidney were degraded by the ubiquitin-
proteasome pathway (43). Other studies showed that HNE-modified proteins, such as HNE-
modified glucose-6-phosphate dehydrogenase, were resistant to proteasome-dependent 
degradation (44) and in some cases the HNE-modified proteins acted as potent noncompetitive 
inhibitors of the proteasome (44, 45). A recent paper showed that histones and other proteins 
treated with low levels of HNE (<100 µM) were better substrate for the 20S proteasome (46). 
However, proteins modified with higher levels of HNE (>100 µM) were resistant to degradation 
by the proteasome (46). The demonstration that HNE-modified proteins are degraded by the 
ubiquitin-dependent lysosomal pathway reconciles the apparent differences in opinion regarding 
which proteolytic pathways are responsible for the degradation of HNE-modified proteins. 
Ubiquitin-dependent lysosomal degradation was involved in regulation of several membrane 
proteins, particularly receptor proteins (42, 47, 48). Ubiquitination of these membrane proteins 
triggers their internalization and targets them for degradation by the lysosome pathway. Similar 
to many other proteins that are degraded by the ubiquitin-dependent lysosomal pathway, the 
majority of the ubiquitinated HNE-modified proteins were mono-ubiquitinated (Figs. 3 and 6B). 
This work showed that not only membrane receptors, but also HNE-modified membrane or 
intracellular proteins, are removed from the cells by the ubiquitin-dependent lysosomal pathway. 
Considering that both membrane receptors and HNE-modified proteins are monoubiquitinated 
and degraded by the lysosome, it is tempting to speculate that they are recognized by the same or 
similar ubiquitin ligases, such as c-Cbl. 
Selective degradation of damaged proteins is essential for cellular functions. The ubiquitin 
conjugating system provides a mechanism to distinguish damaged or adversely modified proteins 
from native proteins. Identification of the enzymes that are required for the recognition and 
ubiquitination of various types of modified or damaged proteins will help to understand the 
Page 9 of 20
(page number not for citation purposes)
 molecular mechanisms of the cellular protein quality control system and will provide clues for 
prevention and/or treatment of diseases that are related to the accumulation of damaged proteins, 
such as cataract and other age-related degenerative diseases. 
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Figure 1. Formation of HNE-protein adducts. Lane 1 is α-crystallin not treated with HNE. Lanes 2–5 are α-crystallins 
exposed to 25, 50, 100, and 200 µM HNE, respectively, for 2 h at 37°C. Lower panel) Protein profiles of α-crystallins 
isolated from bovine lenses after incubation with HNE (Coomassie Blue staining). Upper panel) modification of α-
crystallins by HNE as determined by Western blotting with antibodies to HNE-modified proteins. 
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Figure 2. Ubiquitination and degradation of HNE-modified αB-crystallin. 125I-labeled recombinant αB-crystallin 
was incubated with or without 100 µM HNE for 2 h at 37°C . After removal of unreacted HNE, 125I-labeled αB-crystallins 
were incubated in proteasome-free fraction II prepared from rabbit reticulocyte lysate in the presence or absence of 
ubiquitin. A) Ubiquitination of HNE-modified αB-crystallin: Lanes 1, 3, 5, and 7 are unmodified αB-crystallin and lanes 
2, 4, 6, and 8 are HNE-modified αB-crystallins. Lanes 1, 2, 5 and 6 show formation of ubiquitin conjugates in the 
presence of ubiquitin and lanes 3, 4, 7, and 8 are negative control after incubation without ubiquitin. Formation of 
ubiquitin-125I-labeled αB-crystallin conjugates was assessed by autoradiography following SDS-PAGE and transferring to 
nitrocellulose membrane (lanes 1-4), and the ubiquitin conjugates were confirmed by Western blotting with antibody to 
ubiquitin (lanes 5-8). B) degradation of HNE-modified αB-crystallin. Percent degradation was calculated from acid-
soluble radioactivity recovered in supernatants after 2 h of incubation with reticulocyte lysate at 37°C. Values are means ± 
SD of 4 independent determinations; each was done in duplicate. 
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Figure 3. Effects of different protease inhibitors on the stability of HNE-modified αB-crystallin delivered into lens 
cells. αB-Crystallin was iodinated and modified by HNE as described in Fig. 2. 125I-αB-crystallins were delivered into 
cultured human lens epithelial cells using the BioPORTER protein delivery reagent. Levels of 125I-αB-crystallins (middle 
panel) and the putative mono-ubiquitnated 125I-αB-crystallins (upper panel) were determined after incubation in the 
absence or presence of indicated inhibitors for 4 h. Autoradiograms were scanned, and levels of 125I-αB-crystallins in the 
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Figure 4. Removal of HNE-modified proteins in human lens epithelial cells. Cells were treated with 5 µM HNE for 1 
h and allowed to recover in a medium with or without 40 µM MG132 for 0-24 h. Cells were collected, and an equal 
amount of protein (30 µg) from cell lysate was analyzed by Western blotting with antibodies to HNE-conjugated proteins. 
Upper panel ) Typical Western blotting result. Lower panel) Densitometry quantification of HNE-modified proteins in 
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Figure 5. Effects of protease inhibitor on removal of HNE-modified proteins from lens epithelial cells. Cells were 
treated with 5 µM HNE for 1 h and allowed to recover in a medium contains different protease inhibitors for 4 h. Cells 
were then collected and an equal amount of protein (30 µg) from the cell lysate was analyzed by Western blotting with 
antibodies to HNE-conjugated proteins. Lane 1, untreated cells; lane 2; cells treated with HNE for 1 h; lane 3, recovered 
without any inhibitor; lane 4, recovered in the presence of MG132; lane 5, recovered in the presence of clasto-lactacystin-
β-lactone; lane 6, recovered in the presence of epoxomicin; lane 7, recovered in the presence of chloroquine . Upper 
panel) Typical Western blotting result. Lower panel) Densitometry quantification of HNE-modified proteins in the cells. 
Data in the lower panel are means ± SD of 3 independent experiments. 
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Figure 6. HNE-modified proteins are ubiquitinated in lens cells. A) ATP-dependent removal of HNE-modified 
proteins. Human lens epithelial cells were treated with 5 µM HNE for 1 h and allowed to recover in a normal medium or 
in a medium containing antimycin A and 2-deoxyglucose for 4 h. The cells were collected and an equal amount of protein 
(30 µg) from cell lysate was analyzed by Western blotting with antibodies to HNE-conjugated proteins (upper panel) or 
antibodies to ubiquitin (lower panel). B) Ubiquitination of HNE-modified proteins in cells. Cells were infected with a 
control virus or with a recombinant adenovirus encoding (His)6-tagged ubiquitin for 48 h, and then cells were treated with 
HNE for 1 h. Ubiquitin conjugates were isolated from the cell lysate by Ni-NTA resin and resolved by SDS-PAGE. Lanes 
1 and 2 were probed with antibodies to ubiquitin, and lanes 3 and 4 were identical samples as lanes 1 and 2 but probed 
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Fig. 7 
 
                    
Figure 7. Hypothesis of ubiquitin-dependent protein quality control mechanism. We hypothesize that many proteins 
have internal signal for ubiquitination as indicated by “DEG” in the diagram. Ubiquitination signal is hidden in the native 
conformation, and therefore native proteins are not recognized by the ubiquitination machinery. However, various 
modifications and damage may cause protein unfolding and exposure of ubiquitination signal. Thus, the unfolded proteins 
will be recognized by the combination of specific E2 s and E3 s and be ubiquitinated. Specific modification, such HNE, 
may serve as the signal for ubiquitination. Poly-ubiquitinated proteins will be recruited to the 26S proteasome for 
degradation, and mono-ubiquitinated proteins may enter into the lysosome for degradation. 
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